

Innovation at Work New Mexico




Total Direct and Indirect
Economic Output of the
Biopharmaceutical Sector

\$1.5 billion

Total Employment
Supported by the
Biopharmaceutical Sector

6,664



A majority of Americans agree that even if it brings no immediate benefits, basic scientific research that advances the frontiers of knowledge is necessary and should be supported by the federal government.

Local Perspective: Albuquerque, NM



"I support research because in our modern day society knowledge is power. Through research we are able to gain power over disease and make progressions towards a healthier community. Our members of Congress should support research because that is the only way to further our knowledge base to expand our healthful possibilities."

Katelyn Burd, 26, Arthritis
Foundation advocate



New Mexican Adults
Living with Arthritis

22%

Total NIH Award Funding
(FY16)

\$100 million

Research in the Land of Enchantment

University of New Mexico (UNM) Health Sciences Center, Albuquerque, NM

While the standard treatment for asthma is corticosteroids, these drugs are less effective in obese individuals. The Agency for Healthcare Research and Quality (AHRQ) is funding researchers at UNM studying a new treatment that will help to prevent or treat asthma specifically among obese adults.

AbbVie, Las Cruces and Albuquerque, NM

AbbVie is conducting phase III clinical trials to test the safety and efficacy of a new small molecule medication to treat arthritis; a disease that affects over 50 million Americans. The treatment is intended for patients who have tried the standard treatment but have experienced limited success and still suffer from the debilitating symptoms of arthritis.

Lovelace Respiratory Research Institute (LRRI), Albuquerque, NM

Nearly 64% of HIV-infected patients develop respiratory symptoms, with 21% developing chronic obstructive pulmonary disease (COPD). National Institutes of Health (NIH)-funded researchers at LRRI are investigating the role of a specific HIV protein in the development of COPD, which could lead to future preventative or therapeutic interventions for this high-risk population.

SOURCES: NATIONAL INSTITUTES OF HEALTH, PHARMACEUTICAL RESEARCH AND MANUFACTURES OF AMERICAN (PHRMA), CENTERS FOR DISEASE CONTROL AND PREVENTION, A RESEARCH AMERICA SURVEY OF U.S. ADULTS CONDUCTED IN PARTNERSHIP WITH ZOGBY ANALYTICS IN JUNE 2016, AGENCY FOR HEALTHCARE RESEARCH AND QUALITY, CLINICALTRIALS.GOV.